Abstract
FMS-Like-Tyrosine kinase-3 (FLT3) mutations are found in about 30% of cases of acute myeloid leukemia and confer an increased relapse rate and reduced overall survival. Targeting this tyrosine kinase by direction inhibition is the focus of both preclinical and clinical research in AML. Several molecules in clinical development inhibit FLT3, but thus far clinical responses have been limited. Correlative studies from monotherapy trials have established that responses require sustained, effective FLT3 inhibition in vivo. Studies combining FLT3 inhibitors with chemotherapy have demonstrated increased remission rates to date but have yet to produce a survival advantage. Currently the only approved FLT3 inhibitor available for off-label use is sorafenib, which clearly has clinical activity but does not commonly lead to a complete response. Several FLT3 inhibitors are currently being tested as single agents and in combination with chemotherapy, and it seems likely that a clinically useful drug will eventually emerge.
Keywords: Acute myeloid leukemia, FLT3, Tyrosine kinase inhibitors
Current Drug Targets
Title: Bench to Bedside Targeting of FLT3 in Acute Leukemia
Volume: 11 Issue: 7
Author(s): Keith W. Pratz and Mark J. Levis
Affiliation:
Keywords: Acute myeloid leukemia, FLT3, Tyrosine kinase inhibitors
Abstract: FMS-Like-Tyrosine kinase-3 (FLT3) mutations are found in about 30% of cases of acute myeloid leukemia and confer an increased relapse rate and reduced overall survival. Targeting this tyrosine kinase by direction inhibition is the focus of both preclinical and clinical research in AML. Several molecules in clinical development inhibit FLT3, but thus far clinical responses have been limited. Correlative studies from monotherapy trials have established that responses require sustained, effective FLT3 inhibition in vivo. Studies combining FLT3 inhibitors with chemotherapy have demonstrated increased remission rates to date but have yet to produce a survival advantage. Currently the only approved FLT3 inhibitor available for off-label use is sorafenib, which clearly has clinical activity but does not commonly lead to a complete response. Several FLT3 inhibitors are currently being tested as single agents and in combination with chemotherapy, and it seems likely that a clinically useful drug will eventually emerge.
Export Options
About this article
Cite this article as:
W. Pratz Keith and J. Levis Mark, Bench to Bedside Targeting of FLT3 in Acute Leukemia, Current Drug Targets 2010; 11 (7) . https://dx.doi.org/10.2174/138945010791320782
DOI https://dx.doi.org/10.2174/138945010791320782 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Epigenetic Modifiers in Cancer
Current Medicinal Chemistry Myelodysplastic/Myeloproliferative Neoplasms
Current Cancer Therapy Reviews HIV-1 Tat-Mediated Calcium Dysregulation and Neuronal Dysfunction in Vulnerable Brain Regions
Current Drug Targets Nuclear Export as a Novel Therapeutic Target: The CRM1 Connection
Current Cancer Drug Targets The Impact of Molecularly Targeted Therapies Upon the Understanding of Leukemogenesis and the Role of Hematopoietic Stem Cell Transplantation in Acute Promyelocytic Leukemia
Current Stem Cell Research & Therapy A Review of Pharmacological Treatment Options for Lung Cancer: Emphasis on Novel Nanotherapeutics and Associated Toxicity
Current Drug Targets Interferon alpha for Treatment of Chronic Myeloid Leukemia
Current Drug Targets Targeting Notch Pathway in Cancer Diagnostics and Therapeutics: An Emerging Approach
Recent Patents on Anti-Cancer Drug Discovery Signal Transduction Pathways and Transcription Factors as Therapeutic Targets in Inflammatory Disease: Towards Innovative Antirheumatic Therapy
Current Pharmaceutical Design The Use of Structural Biology in Janus Kinase Targeted Drug Discovery
Current Drug Targets Role of Genetics and Epigenetics in Mucosal, Uveal, and Cutaneous Melanomagenesis
Anti-Cancer Agents in Medicinal Chemistry AZT: An Old Drug with New Perspectives
Current Clinical Pharmacology The Influence of Traumatic Lumbar Puncture (TLP) on Outcome of Pediatric Patients
Current Pediatric Reviews Epigenetically - Targeted Therapies for the Treatment of Hematological Malignancies
Current Medicinal Chemistry Antineoplastic Chemotherapy Induced QTc Prolongation
Current Drug Safety Novel Approaches for RNA Interference and their Application in Cancer Therapy
Current Pharmacogenomics Proteasome Inhibitors Therapeutic Strategies for Cancer
Recent Patents on Anti-Cancer Drug Discovery The Chemistry and Bio-Medicinal Significance of Pyrimidines & Condensed Pyrimidines
Current Topics in Medicinal Chemistry Therapeutic Perspectives for cN-II in Cancer.
Current Medicinal Chemistry Red Blood Cell-Encapsulated L-Asparaginase: Potential Therapy of Patients with Asparagine Synthetase Deficient Acute Myeloid Leukemia
Protein & Peptide Letters